B Li1, L Wang2, Q Lu1, W Da3. 1. Department of Gastroenterology, Jiaxing Second Hospital, 1518 North Ring Road, Jiaxing, 314000, Zhejiang, People's Republic of China. 2. Department of Gastroenterology, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University, 600 Yi Shan Road, Shanghai, 200233, People's Republic of China. wanglgly@163.com. 3. Department of Gastroenterology, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University, 600 Yi Shan Road, Shanghai, 200233, People's Republic of China.
Abstract
AIM: Nuclear factor-erythroid 2-related factor-2 (Nrf2) acts as a defense system in the development of nonalcoholic steatohepatitis (NASH). Curcumin is a phenolic compound with lipid regulatory, anti-oxidative, anti-inflammatory and anti-tumorigenic properties that is beneficial in defending against NASH and was recently proved to be an Nrf2 activator. The aim of this study was to evaluate whether Nrf2 activation could be involved in NASH mitigation by curcumin. METHODS: Hepatic, metabolic, and inflammatory parameters, along with hepatic Nrf2 protein expression were explored in adult Sprague-Dawley rats developing high-fat-diet-induced NASH and submitted to curcumin gavage for 6 weeks. RESULTS: Curcumin administration led to lower degrees of hepatic steatosis and inflammation; lower levels of serum aminotransferases, lipids, and homeostasis model assessment of insulin resistance; and lower serum and hepatic contents of tumor necrosis factor-α (TNF-α), interleukin-6, and malondialdehyde. In contrast, higher hepatic contents of glutathione, heme oxygenase-1 and superoxide dismutase were observed in rats with curcumin. Moreover, Nrf2 expression in liver cell nuclei was significantly higher in rats with curcumin. CONCLUSIONS: Curcumin can prevent and ameliorate NASH via lipid reduction, improve insulin resistance, improve anti-inflammatory, and have antioxidant effects, possibly related to its activation of Nrf2.
AIM: Nuclear factor-erythroid 2-related factor-2 (Nrf2) acts as a defense system in the development of nonalcoholic steatohepatitis (NASH). Curcumin is a phenolic compound with lipid regulatory, anti-oxidative, anti-inflammatory and anti-tumorigenic properties that is beneficial in defending against NASH and was recently proved to be an Nrf2 activator. The aim of this study was to evaluate whether Nrf2 activation could be involved in NASH mitigation by curcumin. METHODS: Hepatic, metabolic, and inflammatory parameters, along with hepatic Nrf2 protein expression were explored in adult Sprague-Dawley rats developing high-fat-diet-induced NASH and submitted to curcumin gavage for 6 weeks. RESULTS:Curcumin administration led to lower degrees of hepatic steatosis and inflammation; lower levels of serum aminotransferases, lipids, and homeostasis model assessment of insulin resistance; and lower serum and hepatic contents of tumor necrosis factor-α (TNF-α), interleukin-6, and malondialdehyde. In contrast, higher hepatic contents of glutathione, heme oxygenase-1 and superoxide dismutase were observed in rats with curcumin. Moreover, Nrf2 expression in liver cell nuclei was significantly higher in rats with curcumin. CONCLUSIONS:Curcumin can prevent and ameliorate NASH via lipid reduction, improve insulin resistance, improve anti-inflammatory, and have antioxidant effects, possibly related to its activation of Nrf2.
Authors: Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Gerasimos P Sykiotis; Ioannis G Habeos; Andrew V Samuelson; Dirk Bohmann Journal: Curr Opin Clin Nutr Metab Care Date: 2011-01 Impact factor: 4.294
Authors: M Carmen Ramirez-Tortosa; César L Ramirez-Tortosa; M Dolores Mesa; Sergio Granados; Angel Gil; José L Quiles Journal: Free Radic Biol Med Date: 2009-06-17 Impact factor: 7.376
Authors: Dennis R Petersen; Laura M Saba; Volkan I Sayin; Thales Papagiannakopoulos; Edward E Schmidt; Gary F Merrill; David J Orlicky; Colin T Shearn Journal: PLoS One Date: 2018-05-25 Impact factor: 3.240
Authors: Mandy Heritage; Lesley Jaskowski; Kim Bridle; Catherine Campbell; David Briskey; Laurence Britton; Linda Fletcher; Luis Vitetta; V Nathan Subramaniam; Darrell Crawford Journal: World J Gastrointest Pathophysiol Date: 2017-05-15